MC3R

Melanocortin receptor 3 · P41968 · MC3R on Sugi Atlas →

83,924 patent compounds predicted against MC3R, 60,153 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL63838	0.82	7/20
SCHEMBL70501	0.82	7/20
SCHEMBL91100	0.82	7/20
SCHEMBL70497	0.62	7/20
SCHEMBL71981	0.62	7/20
SCHEMBL71984	0.62	7/20
SCHEMBL91103	0.62	7/20
SCHEMBL130385	0.57	6/20
SCHEMBL136034	0.57	6/20
Argadin (SCHEMBL141316)	0.39	6/20
SCHEMBL91137	0.68	5/20
Eptifibatide (SCHEMBL43237)	0.59	5/20
Amitriptyline (SCHEMBL7824)	1.00	4/20
Prochlorperazine (SCHEMBL18429)	1.00	4/20
Melitracen (SCHEMBL48975)	1.00	4/20
Prochlorperazine (SCHEMBL133595)	0.98	4/20
Melitracen (SCHEMBL121493)	0.97	4/20
Amitriptyline (SCHEMBL41079)	0.97	4/20
Cyclobenzaprine (SCHEMBL38527)	0.63	4/20
Cyclobenzaprine (SCHEMBL41376)	0.61	4/20

Clinical trials — most relevant to MC3R by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis	PHASE4	COMPLETED
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion	PHASE4	RECRUITING
Young Adults With Early-onset Obesity Treated With Semaglutide	PHASE4	COMPLETED
Long Term Extension Trial of Setmelanotide	PHASE2/PHASE3	COMPLETED
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity	PHASE3	COMPLETED
Effects of Acthar on Recovery From Cognitive Relapses in MS	PHASE3	COMPLETED
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway	PHASE3	COMPLETED
ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)	PHASE2	COMPLETED
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis	PHASE2	COMPLETED
A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis	PHASE2	UNKNOWN
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity	PHASE2	COMPLETED
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)	PHASE2	NOT_YET_RECRUITING
RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients	PHASE2	UNKNOWN
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway	PHASE2	COMPLETED
Effects of RM-493 on Energy Expenditure in Obese Individuals	PHASE1	COMPLETED
Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study	EARLY_PHASE1	COMPLETED
Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy	nan	COMPLETED
Vanderbilt Childhood Obesity Registry	nan	COMPLETED
Rare Obesity Cohorts With Food Behavioral Disorders : Better Diagnosis for Better Treatment	nan	RECRUITING
Melanocortin 4 Receptor Mutations and Obesity-associated Diseases	nan	COMPLETED
Sequencing of 14 Genes From Leptin Melanocortin Pathway in Severe Obesity in Childhood.	nan	UNKNOWN
Brain-Derived Neurotrophic Factor in Obesity and Brain Function	nan	COMPLETED
The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry	nan	COMPLETED
Genetic Research of Monogenic Obesity in a Pediatric Cohort With Severe and Early Onset Obesity (GENOBE)	nan	UNKNOWN
A Model for Genetic Susceptibility: Melanoma	nan	ACTIVE_NOT_RECRUITING
The Role of Melanocyte in Basal Cell Carcinoma	nan	UNKNOWN
FACILITY: Feeding the fAmiLy: the Intergenerational approaCh to fIght obesiTY	nan	UNKNOWN
Eating Behavior in Children	nan	COMPLETED
Assessing Obesity Related Risk Factors in Adult Population: A Genetic and Behavioral Study	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a MC3R binder may also engage these)

Protein	Name	Similarity
P32244	—	1.000	P32244 →
MC5R	Melanocortin receptor 5	1.000	landscape →
MC4R	Melanocortin receptor 4	1.000	landscape →
Q8HXX3	—	1.000	Q8HXX3 →
MC2R	Adrenocorticotropic hormone receptor	0.999	landscape →
P56450	—	0.999	P56450 →
P34974	—	0.999	P34974 →
P33033	—	0.999	P33033 →
Q8HYN8	—	0.998	Q8HYN8 →
P70115	—	0.996	P70115 →
Q0Z8I9	—	0.996	Q0Z8I9 →
Q9GLJ8	—	0.996	Q9GLJ8 →
P41149	—	0.995	P41149 →
O97504	—	0.995	O97504 →
P70596	—	0.995	P70596 →
P56451	—	0.993	P56451 →
Q9TU77	—	0.992	Q9TU77 →
Q9Z1S9	—	0.991	Q9Z1S9 →
P35345	—	0.991	P35345 →
P41983	—	0.991	P41983 →
Q9MZV8	—	0.991	Q9MZV8 →
Q9TT23	—	0.990	Q9TT23 →
Q64326	—	0.989	Q64326 →
B0V1P1	—	0.989	B0V1P1 →
Q01727	—	0.987	Q01727 →
Q8BX79	—	0.985	Q8BX79 →
Q864I2	—	0.984	Q864I2 →
O19037	—	0.983	O19037 →
P0C5J4	—	0.983	P0C5J4 →
Q80SS9	—	0.983	Q80SS9 →